companies / t-therapeutics-com
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-04-30 json
| total_raised | 29,700,00029.7M | ○ |
|---|---|---|
| founded | null | |
| hq | Cambridge | |
| industry | unknown | |
| stage | series-a |
T-Therapeutics is a Cambridge, UK biopharmaceutical company developing T cell therapies for cancer and autoimmune disease via its proprietary OpTiMus TCR platform. It serves patients with solid tumors and autoimmune conditions of high unmet need. The platform finds fully human receptors that reach once-undruggable intracellular targets.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2025-11-01 | series-a | 29,700,00029.7M | null | ○ |
Nginx, WordPress 7.0, Lenis 1.1.13, Yoast SEO 27.6, Google Analytics, Google Tag Manager, Slider Revolution, jQuery Migrate 3.4.1, imagesLoaded 4.1.4, parallax.js, PHP, DoubleClick Floodlight
| fact | status | src |
|---|---|---|
| Series A, $29.7M | attributed | ○ |
| existence | self-reported | WEB |
| description | self-reported | WEB |